China Antibody-B (03681) completes sale of Suzhou properties and facilities

According to the Zhitong Finance App, China Antibody-B (03681) issued an announcement regarding the subsidiary's intention to sell Suzhou properties and facilities for 280 million yuan. The Board is pleased to announce that all the prerequisites contained in the sale agreement have been fulfilled and that the sale was completed on November 4, 2026 in accordance with the terms and conditions of the sale agreement. After completion, the target assets are no longer owned by the seller, and the company no longer has any interest in the target assets.

The board of directors believes that completing the sale of target assets reflects the Group's firm determination to transition to an asset-light model. This move will optimize resource allocation and enhance operational flexibility. Furthermore, adhering to the principle of differentiated innovation, the Group will prioritize resources for early R&D and clinical development to create maximum long-term returns for shareholders.